Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

baxter slovakia s.r.o., slovensko - hypertonické roztoky - 87 - varia i

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

herbacos recordati s.r.o., Česká republika - kyselina acetylsalicylová, kombinácie s výnimkou psycholeptík - 07 - analgetica, antipyretica

Európska únia - slovenčina - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - arzén sírového - leukémia, promyelocytická, akútna - antineoplastické činidlá - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene. návratnosť iné akútne myelogenous leukémia subtypes na arzén sírového nebola preskúmala.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

haleon czech republic s.r.o., Česká republika - paracetamol, kombinácie s výnimkou psycholeptík - 07 - analgetica, antipyretica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sanofi-aventis slovakia s.r.o. - vitamíny, iné kombinácie - 91 - multivitamÍny a stopovÉ prvky

Európska únia - slovenčina - EMA (European Medicines Agency)

pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastické činidlá - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.